SKIPPAIN results: Spinal pain response after 8 weeks of SEC showed notable differences between HLA-B27 subgroups. Can subtype pre-determine tx efficacy/response? Abs 0917 #ACR21 #RheumNow @RheumNow https://t.co/FKpCqXpobM https://t.co/WbjjyTIaiG
Links:
Efficacy of Secukinumab and HLA-B27 Subtypes: Results from a Phase IIIb Randomi…
http://ow.ly/Hxw750Gt7uE
07-11-2021